
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SUMO-1 CRISPR/Cas9 KO Plasmid (m) | sc-423588 | 20 µg | $397.00 |
Sumo1 encodes SUMO-1, a ubiquitin-like modifier that is covalently conjugated to lysine residues on target proteins to regulate their localization, stability, and interaction networks. SUMOylation influences diverse cellular processes including DNA damage signaling and repair, chromatin organization, transcriptional control, nuclear transport, and cell-cycle progression through coordinated E1–E2–E3 enzymatic cascades and SUMO-specific proteases. SUMO-1 modification often intersects with ubiquitin-dependent turnover and stress-response pathways, shaping proteostasis and signaling dynamics in the nucleus and cytoplasm. Dysregulated SUMOylation has been linked to mechanisms relevant to cancer biology, neurodegeneration, and immune regulation, making Sumo1 a useful node for pathway-level studies in mouse models and cell systems.
SUMO-1 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Sumo1 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Sumo1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Sumo1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish SUMO-1 protein expression.
This CRISPR knockout system enables efficient generation of Sumo1-deficient cell models for investigation of SUMO-1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.